Page 84 - Read Online

Page 10 of 11 Nguyen et al. J Transl Genet Genom 2018;2:19 I http://dx.doi.org/10.20517/jtgg.2018.20

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary
information files.

Financial support and sponsorship
The study was supported by INSERM and University Paris 7.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Written informed consent was obtained from the patients to participate to this pilot study.

Consent for publication
Written informed consent was obtained from the patients for publication.

Copyright
© The Author(s) 2018.

REFERENCES
1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with
illustrative cases. The Lancet 1896;148:162-5.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. National Comprehensive Cancer Network. About the NCCN clinical practice guidelines in oncology (NCCN guidelines®). Available
from: https://www.nccn.org/professionals. [Last accessed on 5 Nov 2018]
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
5. Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, et al. Molecular classification of infiltrating breast cancer: toward personalized
therapy. Radiographics 2014;34:1178-95.
6. Morigi C. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments
for patients with early breast cancer. Ecancermedicalscience 2017;11:732.
7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
8. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, et al. Gene expression profiling and histopathological characterization
of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. Identification of human triple-negative breast cancer subtypes
and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
10. Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer.
Cancers (Basel) 2014;6:2187-223.
11. Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res
2016;6:1609-23.
12. Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, et al. Triple-negative breast cancer: new perspectives for targeted therapies.
OncoTargets Ther 2015;8:177-93.
13. Bousquet G, Feugeas JP, Ferreira I, Vercellino L, Jourdan N, et al. Individual xenograft as a personalized therapeutic resort for women
with metastatic triple-negative breast carcinoma. Breast Cancer Res 2014;16:401.
14. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast
Cancer Res 2012;14:R11.
15. Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived xenografts: a relevant preclinical model for drug development. J
Exp Clin Cancer Res 2016;35:189.
16. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, et al. Personalizing cancer treatment in the age of
global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther
2011;10:3-8.
17. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, et al. A pilot clinical study of treatment guided by
personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-6.
18. Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic
cancer: a subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets Ther 2017;10:591-6.
19. Bousquet G, Janin A. Patient-derived xenograft: an adjuvant technology for the treatment of metastatic disease. Pathobiology
2016;83:170-6.
20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes.
J Clin Oncol 2009;27:1160-7.